Granted Patent
B2
US 12,552,824 · App. 18/308,842 · Granted Feb 17, 2026
C-mannoside compounds useful for the treatment of urinary tract infections
Inventors:
Michael Joseph Bishop (Research Triangle Park, NC); Eugene L. Stewart (Collegeville, PA); Katherine Louisa Widdowson (San Diego, CA); James Walter Janetka (St. Louis, MO); Laurel Kathryn McGrane (St. Louis, MO)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
Claims (17)
1 . A method of prevention of a FimH-mediated disease in a human in need thereof, comprising administering to the human a pharmaceutical composition comprising a therapeutically effective amount of a compound which is:
or pharmaceutically acceptable salt thereof,
wherein said disease is a bacterial infection and said bacterial infection is a urinary tract infection and wherein said urinary tract infection is recurrent or chronic.
2 . The method as recited in claim 1 , wherein said pharmaceutical composition is administered orally.
3 . The method as recited in claim 2 , wherein said pharmaceutical composition is administered as a tablet.
4 . The method as recited in claim 2 , wherein said pharmaceutical composition is administered as a capsule.
5 . The method of prevention of a FimH-mediated disease of claim 1 , further comprising administering to the human subject another therapeutic agent.
6 . The method of prevention of a FimH-mediated disease of claim 5 , wherein such administration is substantially simultaneous or sequential.
7 . The method of prevention of a FimH-mediated disease of claim 1 , wherein the bacteria is Escherichia coli.
8 . The method of prevention of a FimH-mediated disease of claim 1 , wherein the urinary tract infection is an antibiotic-resistant bacterial infection.
9 . The method of prevention of a FimH-mediated disease of claim 1 , wherein the prevention is prevention of symptoms of the disease to a clinically significant or detectable level.
10 . The method of prevention of a FimH-mediated disease of claim 1 , wherein the prevention is prevention of disease progression.
11 . The method of prevention of a FimH-mediated disease of claim 1 , wherein the administered compound is:
12 . A method of inhibiting FimH activity in a human subject in need thereof comprising administering to the human subject a pharmaceutical composition comprising a therapeutically effective amount of a compound which is
or a pharmaceutically acceptable salt thereof.
13 . The method of inhibiting FimH activity of claim 12 , further comprising administering to the human subject another therapeutic agent.
14 . The method of inhibiting FimH activity of claim 13 , wherein such administration is substantially simultaneous or sequential.
Assignments (4)
CHANGE OF ADDRESS
Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
CHANGE OF ADDRESS
Recorded Jun 17, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 071649/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 4, 2023
From: STEWART, EUGENE L.; BISHOP, MICHAEL JOSEPH; COLANDREA, VINCENT J.; STRAMBEANU, IULIA; LI, YUEHU; WIDDOWSON, KATHERINE LOUISA
To: GLAXOSMTHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 063534/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 4, 2023
From: MCGRANE, LAUREL KATHRYN; JANETKA, JAMES WALTER
To: FIMBRION THERAPEUTICS, INC.
Reel/Frame 063534/0358 →
Continuity (6)
Continuation
PCTIB2019055806
· Jul 8, 2019
Provisional Application
62755588
· Nov 5, 2018
Provisional Application
62695993
· Jul 10, 2018
References Cited (153)
US 6153396A
· Hultgren
· 2000
[cited by applicant]
US 6962791B2
· Hultgren
· 2005
[cited by applicant]
US 7790183B2
· Darouiche
· 2010
[cited by applicant]
US 8937167B2
· Janetka
· 2015
[cited by applicant]
US 9567362B2
· Janetka
· 2017
[cited by applicant]
US 9957289B2
· Janetka
· 2018
[cited by applicant]
US 20080171706A1
· Berglund
· 2008
[cited by applicant]
US 20150175644A1
· Ernst
· 2015
[cited by applicant]
US 20150197536A1
· Labarbera et al.
· 2015
[cited by applicant]
US 20180194792A1
· Janetka
· 2018
[cited by applicant]
US 20190211045A1
· Janetka
· 2019
[cited by applicant]
US 20200002303A1
· Janetka
· 2020
[cited by applicant]
EP 383092
· 1990
[cited by applicant]
WO WO1995014028
· 1995
[cited by applicant]
WO 0100386A1
· 2001
[cited by applicant]
WO WO200110386
· 2001
[cited by applicant]
WO WO2005089733
· 2005
[cited by applicant]
WO WO2011050323
· 2011
[cited by applicant]
WO WO2011073112
· 2011
[cited by applicant]
WO WO2012109263
· 2012
[cited by applicant]
WO WO2012164074
· 2012
[cited by applicant]
WO WO2013134415
· 2013
[cited by applicant]
WO WO2014016361
· 2014
[cited by applicant]
WO WO2014055474
· 2014
[cited by applicant]
WO WO2014100158
· 2014
[cited by applicant]
WO WO2014165107
· 2014
[cited by applicant]
WO WO2014194270
· 2014
[cited by applicant]
WO WO2017021549
· 2017
[cited by applicant]
WO WO2017156508
· 2017
[cited by applicant]
WO WO2017165619
· 2017
[cited by applicant]
WO WO2019076931
· 2019
[cited by applicant]
Gouin et al., “Discovery and Application of FimH Antagonists” Top Med Chem vol. 12 pp. 123-168, DOI: 10.1007/7355_2014_52 (Year: 2014).
[cited by examiner]
Torres et al., “Crohn's disease” The Lancet vol. 389 pp. 1741-1755, DOI: 10.1016/S0140-6736(16)31711-1 (Year: 2016).
[cited by examiner]
Abdel-Megeid, F. et al., “Preparation and Some Reactions of O-Glucosyl Derivatives of 2-Thioxo-1,3,4-Oxadiazoles and 2-Thioxo-1,3,4-Thiadiazoles and Their 2-Oxo Analogues”, Carbohydrate Res., 59(1):95-102, (1977).
[cited by applicant]
Abgottspon, D. et al., “Development of an Aggregation Assay to Screen FimH Antagonists”, J Microb Methods, 82(3):249-55, (2010).
[cited by applicant]
Abgottspon, D. et al., “In Vivo Evaluation of FimH Antagonists—A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection”, Chimia, 66(4):166-9, (2012).
[cited by applicant]
Almant M, Moreau V, Kovensky J, et al. “Clustering of
[cited by applicant]
Aronson M, Medalia O, Schori L, et al. “Prevention of colonization of the urinary tract of mice with
[cited by applicant]
Barras A, Martin FA, Bande O, et al. “Glycan-functionalized diamond nanoparticles as potent
[cited by applicant]
Bognar, R. et al., “N-Glycosyl Derivatives: Part III. The Subsequent Installation of the Aglycone. Synthesis of N-Glycosyl Derivatives of 2-Amino-Thiazole, 2-Amino-1 ,3,4-Thiadiazole and 5-Amino-1 ,2,3,4-Thiatriazols”, …
[cited by applicant]
Bouckaert, J. et al., “Receptor Binding Studies Disclose a Novel Class of High-Affinity Inhibitors of the
[cited by applicant]
Bouckaert J, Li Z, Xavier C, et al. “Heptyl alpha-D-mannosides grafted on a beta-cyclodextrin core to interfere with
[cited by applicant]
Car Z, Hrenar T, Petrović Peroković VP, et al. “Mannosylated N-aryl substituted 3-hydroxypyridine-4-ones: synthesis, hemagglutination inhibitory properties, and molecular modeling,” Chem Biol Drug Des, 84:393-401 (2014).
[cited by applicant]
Chandrasekaran V, Kolbe K, Beiroth F, et al. “Synthesis and testing of the first azobenzene mannobioside as photoswitchable ligand for the bacterial lectin FimH,” Beilstein J Org Chem, 9:223-233 (2013).
[cited by applicant]
Choudhury D, Thompson A, Stojanoff V, et al. “X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic
[cited by applicant]
Cusumano, C. et al., “Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors”, Sci Transl Med., 3(109):109ra115, (2011).
[cited by applicant]
De Ruyck J, Lensink MF, Bouckaert J, “Structures of C-mannosylated anti-adhesives bound to the type 1 fimbrial FimH adhesin,” IUCrJ,3(Pt 3:163-167 (2016).
[cited by applicant]
Durka, M. et al., “The Functional Valency of Dodecamannosylated Fullerenes with
[cited by applicant]
Firon, N. et al., “Aromatic Alpha-Glycosides of Mannose Are Powerful Inhibitors of the Adherence of Type 1 Fimbriated
[cited by applicant]
Firon, N. et al., “Interaction of Mannose-Containing Oligosaccharides With the Fimbrial Lectin of
[cited by applicant]
Furneaux, R. et al., “New Mannotriosides and Trimannosides as Potential Ligands for Mannose-Specific Binding Oroteins”, Can J Chem., 80:964-72, (2002).
[cited by applicant]
Gouin, S. et al., “Synthetic Multimeric Heptyl Mannosides as Potent Antiadhesives of Uropathogenic
[cited by applicant]
Grabosch, C. et al., “Squaric Acid Monoamide Mannosides as Ligands for the Bacterial Lectin FimH: Covalent nhibition or Not?”, Chem Bio Chem., 12(7):1066-74, (2011).
[cited by applicant]
Guiton, P. et al., “Combinatorial Small-Molecule Therapy Prevents Uropathogenic
[cited by applicant]
Han, Z. et al., “Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides”, J Med Chem., 55(8):3945-59, (2012).
[cited by applicant]
Han, Z. et al., “Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists”, J Med Chem., 53(12):4779-92, (2010).
[cited by applicant]
Hartmann, M. et al., “The Bacterial Lectin FimH, a Target for Drug Discovery—Carbohydrate Inhibitors of Type 1 Fimbriae-Mediated Bacterial Adhesion”, Eur J Org Chem., 2011(20-21):3583-3609 (2011).
[cited by applicant]
Haskins, W. et al., “Relations Between Rotatory Power and Structure in the Sugar Group; Some 2′-Naphthyl L-Thioglycopyranosides and their Acetates”, J Am Chem Soc., 69(7):1668-72, (1947).
[cited by applicant]
Hung, C. et al., “Structural Basis of Tropism of
[cited by applicant]
Irani, R. et al., “Stannic Chloride Promoted Synthesis of Mannosides”, Indian J Chem., Sect. B: Org. Chem. Incl. Med. Chem. 30(5):519-21, (1991), (abstract only).
[cited by applicant]
Jarvis C, Han Z, Kalas V, et al, “Antivirulence isoquinolone mannosides: optimization of the biaryl aglycone for FimH lectin binding affinity and efficacy in the treatment of chronic UTI,” ChemMedChem,11(4):367-373 (201…
[cited by applicant]
Jiang, X. et al., “Antiadhesion Therapy for Urinary Tract Infections—A Balanced PK/PD Profile Proved to Be Key for Success”, J Med Chem., 55(10):4700-13, (2012).
[cited by applicant]
Kleeb S, Jiang X, Frei P, et al, “FimH antagonists: phosphate prodrugs improve oral bioavailability,” J Med Chem, 59(7):3163-3182 (2016).
[cited by applicant]
Kleeb S, Pang L, Mayer K, et al, “FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile,” J Med Chem, 58(5):2221-2239 (2015).
[cited by applicant]
Klein, T. et al., “FimH Antagonists for the Oral Treatment of Urinary Tract Infections: From Design and Synthesis to in Vitro and in Vivo Evaluation”, J Med Chem., 53(24):8627-41, (2010).
[cited by applicant]
Kostakioti, M. et al., “Distinguishing the Contribution of Type 1 Pili from That of other QseB-Misregulated Factors When QseC Is Absent during Urinary Tract Infection”, Infect Immun., 80(8):2826-34, (2012).
[cited by applicant]
Kötter S, Krallmann-Wenzel U, Ehlers S, et al, “Multivalent ligands for the mannose-specific lectin on type 1 fimbriae of
[cited by applicant]
Lindhorst, T. et al., “Inhibition of the Type 1 Fimbriae-Mediated Adhesion of
[cited by applicant]
Lindhorst TK, Bruegge K, Fuchs A, et al, “A bivalent glycopeptide to target two putative carbohydrate binding sites on FimH,” Beilstein J Org Chem,6:801-809 (2010).
[cited by applicant]
Mydock-McGrane, L. et al., “Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections”, J Med Chem., 59(20):9390-408, (2016).
[cited by applicant]
Nagahori, N. et al., “Inhibition of Adhesion of Type 1 Fimbriated
[cited by applicant]
Neeser J, Koellreutter B, Wuersch P, “Oligomannoside-type glycopeptides inhibiting adhesion of
[cited by applicant]
Pang, et al., “FimH Antagonists: Structure-Activity and Structure-Property Relationships for Biphenyl a-D-Mannopyranosides,” ChemMedChem 2012, vol. 7, pp. 1404-1422, p. 1408.
[cited by applicant]
Papadopoulos A, Shiao TC, Roy R, “Diazo transfer and click chemistry in the solid phase syntheses of lysine-based glycodendrimers as antagonists against
[cited by applicant]
Qian, X. et al., “Arrays of Self-Assembled Monolayers for Studying Inhibition of Bacterial Adhesion”, Anal Chem., 74(8):1805-10, (2002).
[cited by applicant]
Rabbani, S. et al., “Expression of the Carbohydrate Recognition Domain of FimH and Development of a Competitive Binding Assay”, Anal Biochem., 407(2):188-95, (2010).
[cited by applicant]
Sattigeri, J. et al., “Synthesis and Evaluation of Thiomannosides, Potent and Orally Active FimH Inhibitors”, Bioorg Med Chem Lett., 28(17):2993-2997, (2018).
[cited by applicant]
Scharenberg, M. et al., “Target Selectivity ofFimH Antagonists”, J Med Chem., 55(22):9810-6, (2012).
[cited by applicant]
Scharenberg, M. et al., “A Flow Cytometry-Based Assay for Screening FimH Antagonists”, Assay Drug DevTechnol., 9(5):455-65, (2011).
[cited by applicant]
Schierholt A, Hartmann M, Lindhorst TK, “Bi- and trivalent glycopeptide mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: variation of valency, aglycon and scaffolding,” Carb Res,346:1519-15…
[cited by applicant]
Schönemann W, Kleeb S, Dätwyler P, et al, Prodruggability of carbohydrates—oral FimH antagonists, Can J Chem,94 (11):909-919 (2016).
[cited by applicant]
Schonemann, et al., “Improvement of Agylcone π-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists,”
[cited by applicant]
Schwardt, 0. et al., “Design, Synthesis and Biological Evaluation of Mannosyl Triazoles as FimH Antagonists”, Bioorg Med Chem., 19(21):6454-73, (2011).
[cited by applicant]
Shuman, D. et al., “Synthesis and Biological Activity of Certain 8-Mercaptopurine and 6-Mercaptopyrimidine S-Nucleosides”, J Med Chem., 12(4):653-7, (1969).
[cited by applicant]
Sperling, O. et al., “Evaluation of the Carbohydrate Recognition Domain of the Bacterial Adhesion FimH: Design, Synthesis and Binding Properties of Mannoside Ligands”, Org Biomol Chem., 4(21):3913-3922, (2006).
[cited by applicant]
Stoll, Van A. et al., “The Furocoumarin and the Beta-D-Glucosido-Furocumarinsaure from the Seeds of
[cited by applicant]
Taile, V. et al., “Synthesis and Biological Evaluation of Novel 2(4-O-beta-D glucosidoxyphenyl) 4,5-Disubstituted Imidazoles”, J Heterocyclic Chem., 47(4):903-7, (2010).
[cited by applicant]
Tomašić T, Rabbani S, Gobec M, et al, “Branched: a-D-mannopyranosides: a new class of potent FimH antagonists,” Med Chem Commun,5(8):1247-1253 (2014).
[cited by applicant]
Touaibia, M. et al., “Glycodendrimers as Anti-Adhesion Drugs Against Type 1 Fimbriated
[cited by applicant]
Touaibia, M. et al., “Mannosylated G(0) Dendrimers with Nanomolar Affinities to
[cited by applicant]
Touaibia, M. et al., “Tri- and Hexavalent Mannoside Clusters as Potential Inhibitors of Type 1 Fimbriated Bacteria Using Pentaerythritol and Triazole Linkages”, Chem Commun., (4):380-2, (2007).
[cited by applicant]
Walter, M. et al., “A Modular System for the Preparation of Diazirine-Labeled Mannose Derivatives Using Thiourea Bridging”, Synthesis, 6:952-8, (2006).
[cited by applicant]
Wellens, A. et al., “Intervening with Urinary Tract Infections Using Anti-Adhesives Based on the Crystal Structure of the FimH-Oligomannose-3 Complex”, PLoS ONE, 3(4):e2040, (2008).
[cited by applicant]
Written Opinion and International Search Report issued in PCT/IB2019/055806, dated Oct. 16, 2019.
[cited by applicant]
International Preliminary Report on Patentability issued in PCT/IB2019/055806, dated Jun. 5, 2020.
[cited by applicant]
Banker G.S., et al., “Modern Pharmaceutics Third Edition, Revised and Expanded,” Marcel Dekker, New York, 1996, p. 596, (2 Pages).
[cited by applicant]
Communication Under Rule 71(3) EPC (Notice of Allowance) for European Application No. 12744161.6, dated Nov. 9, 2018, 7 Pages.
[cited by applicant]
Communication Under Rule 71(3) EPC (Notice of Allowance) for European Patent Application No. 10825785.8, mailed Jul. 14, 2016, 5 Pages.
[cited by applicant]
Communication Under Rule 71(3) EPC (Notice of Allowance) for European Patent Application No. 10825785.8, mailed Aug. 23, 2018, 5 Pages.
[cited by applicant]
Communication Under Rule 71(3) EPC (Notice of Allowance) for European Patent Application No. 10825785.8, mailed Feb. 26, 2018, 5 Pages.
[cited by applicant]
Co-Pending U.S. Appl. No. 16/087,305, filed Sep. 21, 2018, 80 Pages,.
[cited by applicant]
Cusumano C., et al., “Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors,” www. ScienceTranslationalMedicine.org, Nov. 16, 2011, vol. 3, No. 109: 109ra115, pp. 1-10 (22 Pages).
[cited by applicant]
European Search Report from related European Patent Application No. 10825785.8, dated Jan. 7, 2014, 10 pages.
[cited by applicant]
Extended European Search Report for European Application No. 12744161.6, mailed Aug. 6, 2014, 13 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 14804252.6, mailed Dec. 23, 2016, 9 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 17764270.9, mailed Jul. 15, 2019, 6 Pages.
[cited by applicant]
Extended European Search Report for European Application No. 18214928.6, mailed Apr. 29, 2019, 8 Pages.
[cited by applicant]
Fatima S., et al., “Application of Butenonyl-c-glucosides in the Synthesis of Pyrazolinyl-, Aminopyrimidinyl and Biphenyl Methyl-ß-d-c-glucopyranosides,” Molecular Diversity, 2011, vol. 15, No. 3, 6 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 13/453,991, mailed Mar. 6, 2014, 9 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 15/915,490, mailed Feb. 24, 2020, 9 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/353,824, mailed Feb. 25, 2020, 07 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 13/453,991, mailed Nov. 20, 2013, 14 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/570,322, mailed May 20, 2016, 8 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/894,927, mailed Mar. 3, 2017, 10 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/373,260, mailed Feb. 26, 2018, 5 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/915,490, mailed Aug. 29, 2019, 12 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/087,305, mailed Dec. 31, 2019, 19 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/353,824, mailed Nov. 6, 2019, 7 Pages.
[cited by applicant]
Notice of Allowance and Fees Due for U.S. Appl. No. 13/453,991, mailed Jul. 14, 2014, 7 Pages.
[cited by applicant]
Notice of Allowance and Fees Due for U.S. Appl. No. 14/570,322, mailed Sep. 9, 2016, 8 Pages.
[cited by applicant]
Notice of Allowance and Fees Due for U.S. Appl. No. 14/894,927, mailed Dec. 8, 2017, 7 Pages.
[cited by applicant]
Notice of Allowance and Fees Due for U.S. Appl. No. 14/894,927, mailed Aug. 16, 2017, 5 Pages.
[cited by applicant]
Notice of Allowance and Fees Due for U.S. Appl. No. 15/373,260, mailed Nov. 21, 2018, 7 Pages.
[cited by applicant]
Notice of Allowance and Fees Due for U.S. Appl. No. 15/373,260, mailed Oct. 23, 2018, 7 Pages.
[cited by applicant]
Notice of Allowance and Fee(s) Due related to U.S. Appl. No. 13/453,991, dated Sep. 4, 2014, 11 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/373,260, mailed Jul. 2, 2018, 5 Pages.
[cited by applicant]
Notice of Reasons for Refusal for Japanese Patent Application No. 2016-517061, dated Dec. 19, 2017, 13 Pages, Including Partial English Translation.
[cited by applicant]
Notice of Reasons for Refusal for Japanese Patent Application No. 2016-517061, dated Jul. 31, 2018, 12 Pages.
[cited by applicant]
Office Action for Australian Application No. 2014273962, dated Oct. 11, 2018, 5 Pages.
[cited by applicant]
Office Action for Chinese Application No. 201480043010.1, mailed Apr. 19, 2019, 12 Pages.
[cited by applicant]
Office Action for Chinese Application No. 201480043010.1, mailed Oct. 30, 2017, 21 Pages, Including English Translation.
[cited by applicant]
Office Action for Chinese Patent Application No. 201480043010.1, dated Oct. 8, 2019, 13 Pages.
[cited by applicant]
Office Action for European Application No. 10825785.8, mailed Jun. 23, 2017, 5 Pages.
[cited by applicant]
Office Action for European Application No. 12744161.6, mailed Aug. 15, 2018, 3 Pages.
[cited by applicant]
Office Action for European Application No. 14804252.6, mailed Oct. 17, 2019, 6 Pages.
[cited by applicant]
Office Action for European Patent Application No. 12744161.6, mailed Mar. 17, 2017, 4 Pages.
[cited by applicant]
Office Action for European Patent Application No. 14804252.6, mailed Feb. 12, 2019, 10 Pages.
[cited by applicant]
Second Office Action for Chinese Application No. 201480043010.1, dated Aug. 24, 2018, 18 Pages, including English Translation.
[cited by applicant]
Wolff M.E., “Burger's Medicinal Chemistry and Drug Discovery,” John Wiley Sons, 5th Edition, Part 1, 1995, vol. I, pp. 975-977 (8 Pages).
[cited by applicant]